Pro-inflammatory activity of NF-κB has been implicated in bladder cancer progression therefore, we speculate that inhibitors of SETD6 that can inhibit lysine methylation of p65 can be a potential therapeutic strategy for bladder cancer. The gene discussed is SETD6; the disease is urinary bladder carcinoma.